<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tapentadol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06204</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Opioid analgesic for treatment of moderate to severe pain. <span class="caps">FDA</span> approved on Nov 20, 2008.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06204/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06204/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06204.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06204.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06204.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06204.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06204.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06204">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>CG-5503</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Tapentadol Hydrochloride </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000169/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000169/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: ZELFLGGRLLOERW-YECZQDJWSA-N</li>
              <li>Monoisotopic Mass: 257.154642102</li>
              <li>Average Mass: 257.799</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000169">DBSALT000169</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Nucynta</td><td>Janssen Pharmaceuticals, Inc.</td></tr><tr><td>Palexia</td><td>Gr&#252;nenthal Ltd</td></tr><tr><td>TAPAL </td><td>MSN Labs </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>175591-23-8</td></tr><tr><th>Weight</th><td>Average: 221.3385<br>Monoisotopic: 221.177964363</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>23</sub>NO</td></tr><tr><th>InChI Key</th><td>KWTWDQCKEHXFFR-SMDDNHRTSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenylpropylamines</td></tr><tr><th>Direct parent</th><td>Phenylpropylamines</td></tr><tr><th>Alternative parents</th><td>Phenols and Derivatives; Tertiary Amines; Polyamines; Enols</td></tr><tr><th>Substituents</th><td>phenol derivative; tertiary amine; enol; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>The immediate-release formulation of tapentadol is indicated for the relief of moderate to severe acute pain. The long-acting formulation serves as a continuous, around-the-clock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy. </td></tr><tr><th>Pharmacodynamics</th><td>Tapentadol is a centrally-acting synthetic analgesic. It is 18 times less potent than morphine in terms of binding to human mu-opioid receptors. It also increases norepinephrine concentrations in the brains of rats via inhibition of norepinephrine reuptake. Selective mu-opioid antagonists like naloxone can block analgesia from tapentadol. It also has not effect on the QT interval. </td></tr><tr><th>Mechanism of action</th><td>Tapendadol causes large increases in levels of extracellular norepinephrine (NE) due to a dual mechanism of action involving mu opioid receptor (MOR) agonism as well as noradrenaline reuptake inhibition.

</td></tr><tr><th>Absorption</th><td>Bioavailability, immediate release (IR), 86 mg: 32%; 
Bioavailability, extended release (ER), 86 mg: 32%; 
Cmax, IR: 64.2 ng/mL;
Cmax, ER: 22.5 ng/mL; 
T max, IR: 1.5 hours;
T max, ER: 5.0 hours;
Tapentadol accumulates following multiple repeat doses.  

</td></tr><tr><th>Volume of distribution</th><td><p>Following IV administration, volume of distribution is 540 &#177; 98 L.</p></td></tr><tr><th>Protein binding</th><td>~20% </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>97% of the dose is metabolized mostly via conjugation with glucuronic acid to produce glucuronides. Tapentadol is also metabolized into N-desmethyl tapentadol (13%) by CYP2C9 and CYP 2C19. CYP2D6 is involved in the formation of the metabolite, hydroxy tapentadol (2%). All metabolites are inactive. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Tapentadol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00934">N-desmethyl tapentadol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/955">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Tapentadol and its metabolites are excreted almost exclusively (99%) via the kidneys.  Approximately 70% (55% O-glucuronide and 15% sulfate of tapentadol) is excreted in conjugated form. A total of 3% of drug was excreted in urine as unchanged drug. </td></tr><tr><th>Half life</th><td>Elimination half-life, IV: 4 hours. </td></tr><tr><th>Clearance</th><td><p>Total clearance = 1530 &#177; 177 ml/min.</p></td></tr><tr><th>Toxicity</th><td>Oral, rabbit: LD50 = 3200 mg/kg;
Oral, mouse: LD50 = 300 mg/kg;
Oral, rat: LD50: 980 mg/kg;
The most common reasons for discontinuation due to adverse events were dizziness, nausea, vomiting, somnolence, and headache. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9937</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9232</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7912</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.559</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9304</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9408</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6918</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8085</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.5219</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5509</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6665</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8856</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5538</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.921</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8389</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8875</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6862
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5177
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9421
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6035 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7187
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6155
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Ortho mcneil janssen pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Oral</td><td>20 mg/mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>50 mg, 75 mg, 100 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>50 mg, 100 mg, 150 mg, 200 mg, 250 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00788">Naproxen</a></td><td>Increases the AUC of tapentadol by 17%. These changes are not considered clinically relevant and no change in dose is required.</td></tr><tr><td><a href="/drugs/DB01032">Probenecid</a></td><td>Increases the AUC of tapentadol by 57%. These changes are not considered clinically relevant and no change in dose is required.</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Increases the toxicity of tapentadol by unknown mechanism. Discontinue rasagiline at least 14 days prior to tapentadol administration. </td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>Increases the toxicity of tapentadol by unknown mechanism. Discontinue selegiline at least 14 days prior to tapentadol administration. </td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Use of two serotonin modulators, such as zolmitriptan and tapentadol, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Food increases the AUC and Cmax of tapentadol. Despite this, tapentadol can be given without regards to food.</li></ul></td></tr></tbody></table>